Search

Search Constraints

You searched for: Author/Creator Karajannis, Matthias

Search Results

21. IMMU-08. PHASE I TRIAL (NCT02457845) SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF IMMUNOVIROTHERAPY WITH HSV G207 IN CHILDREN WITH PROGRESSIVE MALIGNANT SUPRATENTORIAL BRAIN TUMORS. Issue 2 (22nd June 2018)

24. LGG-07. CLINICAL FEATURES OF NON-CANONICAL MOLECULAR DRIVERS IN PLGG; AN UPDATE FORM THE INTERNATIONAL PLGG TASKFORCE. (23rd April 2019)

25. LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. (23rd April 2019)

26. LGG-50. INTEGRATED MOLECULAR AND CLINICAL ANALYSIS OF 1, 000 PEDIATRIC LOW-GRADE GLIOMAS UNCOVERS NOVEL SUBGROUPS FOR CLINICAL RISK STRATIFICATION. (4th December 2020)

27. LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. (4th December 2020)

28. LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. Issue 2 (22nd June 2018)

29. NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS. (4th December 2020)

30. NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Issue 2 (22nd June 2018)